WO

Will Olsen

Founder of Engage Bio (Non-Viral DNA Therapies)

Menlo Park, California

Invests in

Stages:

  • Min Investment:

    $200,000.00
  • Max Investment:

    $300,000.00
  • Target Investment:

    $250,000.00

Work Experience

2021

  • Co-Founder & CEO

    2021

    Engage Bio is developing Tethosomes, the next generation of non-viral DNA medicines. Tethosomes are highly potent, non-immunogenic, redosable, and titratable. At Engage, we're focused on building genetic medicines that scale. www.engagebio.com

  • Venture Partner

    2019

  • Vice President of Development Operations

    2019 - 2021

    Developing TERT mRNA therapy to extend telomeres and increase the human healthspan.

  • Co-founder and Chief Operating Officer

    2015 - 2020

    Diagnostic platform for early detection of liver disease. Acquired by diagnostic developer DiscernDx.

2013 - 2015

  • Senior Program Manager

    2015 - 2015

    Designed and managed early-phase clinical programs. Participated in business development, including bid defenses and acting as technical sales lead.

  • Program Manager

    2013 - 2015

  • Research Associate

    2012 - 2013

  • Economic Analyst Intern

    2010 - 2010